Cell therapy manufacturing is uniquely vulnerable to contamination, variability, and operational burden because the product - ...

Upperton Pharma Solutions submits MHRA application for a new Annex 1–compliant sterile manufacturing facility, expanding clinical-scale CDMO capacity for biotech and pharma companies.

Ottawa, Jan. 08, 2026 (GLOBE NEWSWIRE) -- The CDMO aseptic filling solutions market is experiencing robust growth and is expected to continue booming throughout the prospective period, propelled by ...

An interview with Gilberto Dalmaso, discussing the different grades of pharmaceutical cleanrooms and the production of high-level compounds under aseptic conditions. Please give an overview of ...

As demands for aseptic manufacturing increase, partnerships with solutions providers will be key to ensuring safe, versatile and optimized drug containment.

In drug manufacturing, aseptic filling is the crucial final step in advancing biologics candidates into the clinic. Whether drug manufacturers outsource the process to a CDMO or bring the filling ...

For the third time in recent months, the FDA has slammed a Japanese drug company in a warning letter, this time for not doing enough to prevent contamination during aseptic filling. The most recent ...

The new system seamlessly integrates Dara aseptic fill-and-finish systems with Getinge La Calhene’s isolator technology to achieve a class 100 cleanroom working environment when operating the system ...

Why is aseptic processing important in pharmaceutical manufacturing? The manufacturing of both sterile drugs and biological products can be achieved through terminal sterilization or aseptic ...

The growing concern to maintain pharmacological efficacy and product quality, to ensure patient's safety, has led to a greater focus on the need for aseptic fill / finish; drug developers prefer to ...